In a notable legal shift, a coalition of anti-abortion medical groups and physicians has officially withdrawn their lawsuit challenging the U.S. government’s approval of the abortion pill mifepristone. This decision, made in a federal court in Amarillo, Texas, comes five months after the U.S. Supreme Court unanimously ruled that these groups lacked the legal standing to pursue their case against the Food and Drug Administration (FDA).
The plaintiffs, including the Alliance for Hippocratic Medicine and the American Association of Pro-Life Obstetricians and Gynecologists, had initially sought to have mifepristone removed from the market entirely. Their efforts were met with significant legal hurdles, culminating in the Supreme Court’s ruling that effectively dismissed their claims. Although they have dropped their case without prejudice—leaving the door open for potential future refiling—their decision reflects the challenges they would likely face under the current judicial landscape.
Julie Blake, senior counsel at Alliance Defending Freedom, which represents the plaintiffs, expressed support for three Republican-led states—Idaho, Missouri, and Kansas—that are now seeking to continue the fight against mifepristone’s accessibility. These states argue that the FDA’s deregulation of mifepristone undermines their authority to enforce state-level abortion restrictions and has led to increased healthcare costs associated with treating complications from its use.
Mifepristone is a critical component of medication abortions in the United States, which account for a significant majority of all abortion procedures. The FDA has maintained that mifepristone is safe and effective, having monitored its use for over two decades. However, following a 2023 ruling by U.S. District Judge Matthew Kacsmaryk that temporarily suspended the FDA’s approval of the drug, subsequent appeals have highlighted ongoing tensions surrounding its regulation.
The states’ new legal strategy seeks to reimpose pre-2016 restrictions on mifepristone, which included limiting its use to within seven weeks of pregnancy and requiring in-person consultations for prescriptions. The FDA argues that this lawsuit lacks merit since it was initiated without the original plaintiffs who lacked ties to Texas.
As this legal battle unfolds, uncertainty looms regarding how an incoming Republican administration might approach mifepristone regulations. President-elect Donald Trump has previously stated he would not ban the drug; however, his administration’s stance on potential restrictions remains unclear.
The case is officially titled Food and Drug Administration v. Alliance for Hippocratic Medicine*, U.S. Supreme Court No. 23-235.
Read more: